Program Book

(cargusale@yahoo.com)
Oncology Service, Wills Eye Institute, Philadelphia
Purpose. To report the spectrum of iris lesions from a single ocular
oncology center
Methods. Retrospective review of medical records
Results. Of 3451 patients, the mean age at presentation was 48 years
(median 50 years, range 2 week to 95 years). There were 1423 males
(41%) and 2028 females (59%). Of 3680 lesions, 2907 (79%) were
benign and 773 (21%) were malignant, while 768 were cystic (21%)
and 2912 (79%) solid. Specific diagnoses included nevus (41%), iris
pigment epithelium (IPE) cyst (18%), melanoma (18%), freckle (3%),
Lisch nodules (2%), melanocytoma (2%), melanocytosis (2%), and
other (15%). Lesions were located in the iris stroma (80%) and IPE
(20%). Most common diagnostic categories within solid lesions were
melanocytic (68%), non-melanocytic (11%), vascular (2%), metastasis
(2%) and pseudotumors (5%).
Conclusions. Of 3680 iris lesions, 79% were benign; and the most
common diagnosis included nevus (41%), IPE cyst (18%), melanoma
(18%), and freckle (3%).
Financial disclosure. None
111 OT2
CLINICAL AND OCT FINDINGS ON SYMPTOMATIC
MACULAR NAEVI TREATED WITH INTRAVITREAL
ANTI-VEGF
Sonia A. Callejo, Mikael Sebag, Marc Blouin, Christine Corriveau
(guilleyso@hotmail.com)
Centre Hospitalier de l’Universite de Montreal CHUM Canada
Purpose. To report the clinical and OCT findings of patients with
symptomatic macular naevi treated with intraocular anti-VEGF.
Methods. Retrospective small case series of 8 patients diagnosed
with macular choroidal naevus with impared visual acuity treated
with intravitreal anti-VEGF. Clinical information, serial color
fundus photography, FA, OCT findings and ultrasonographic tumor
measurements were reviewed and compared before and after anti-VEGF
treatment.
Results. 8 patients: 4 males and 4 females. Mean age at presentation:
63 years (range 49 to 54). Mean follow up: 3 ½ years (range 7 months-9
1/2 years). Mean number of anti-VEGF injections: 7.5 (range: 1 to 17).
The largest naevus basal diameter was 7.3mm and the median thickness
was 2.1mm. No ultrasonographic evidence of tumor enlargement or
transformation into melanoma was documented following treatments.
Large fluctuations in VA were recorded prior to anti-VEGF injections.
Reduction in the degree of fluctuation was noticed during anti-VEGF
treatments. Anti-VEGF treatment was associated with resolution or
decreased of exudative retinal detachment, retinal thickness, cystic
retinal changes (4 cases), subretinal fluid (6 cases), pigmented
epithelium detachment (PED) (3 cases) and subretinal/intraretinal
blood associated (1 case) or not (2 cases) to the presence of a choroidal
endovascular membrane.
Conclusions. Although a larger study is needed, the use of intraocular
anti-VEGF treatment of symptomatic macular naevi is promising based
on the improvement of clinical and OCT parameters as well as the
stability of tumor measurements.
Financial disclosure. None
EYELID, CONJUNTIVA & ORBIT
Abstracts
71
1340 OT3
RISK FACTORS FOR GROWTH OF POSTERIOR UVEAL
MELANOCYTIC LESIONS WITH THICKNESS GREATER
THAN 2 MM IN 161 CONSECUTIVE PATIENTS
Patrick De Potter, Audrey Noel, Jacques Jamart
(patrick.depotter@uclouvain.be)
Ocular Oncology Unit, Centre du Cancer, Cliniques Universitaires St Luc,
Brussels, Belgium.
Centre de Biostatistique et de Documentation médicale, Cliniques
Universitaires de Mont-Godinne, Yvoir, Belgium
Purpose. To better define the clinical and ultrasonographic risk factors
predictive of growth of small melanocytic posterior uveal tumors
presenting with a thickness of 2 mm or more as the only clinical suspicious
factor predictive of tumor growth at first visit.
Methods. Non comparative observational cases series including 161
patients with suspicious choroidal or cilio-choroidal tumors measuring
2 mm or more in thickness and no other clinical factors predicting of
growth such as orange pigment, subretinal fluid, tumor margin touching
disc, or tumor-related visual symptoms at initial visit. Those 161 patients
were followed since October 1997 to document growth prior to treatment.
Kaplan-Meier analysis was used to assess time to tumor growth and Cox
proportional hazards regressions evaluated factors predictive of tumor
growth
Results. The mean age at diagnosis was 65 years old. The mean largest
tumor diameter was 9 mm (range, 3 to 16 mm) and tumor thickness 2,6
mm (range, 2 to 5,6 mm). The mean distance to the disc was 5,7 mm
(range, 0,5 to 15 mm) and to the fovea 5,2 mm (range, 0 to 16 mm). Of
the 161 small melanocytic lesions, 31 (19%) demonstrated growth after a
mean follow-up of 32 months (range, 6 to 116 months). One patient (0.6%)
developed systemic metastasis. The factors predictive of growth included
greater tumor diameter, greater tumor thickness, lack of drusen, and
acoustic hollowness. The global cumulative risks for tumor growth were
4% at one year, 17% at 3 years, 22% at 5 years, and 27% at 10 years.
Conclusions. Among posterior uveal melanocytic lesions with tumor
thickness greater than 2.0 mm as the only clinical factor predictive of
growth at initial visit, those with greater diameter, greater thickness,
acoustic hollowness and lack of overlying drusen carried a significant risk
for growth and should be monitored with regular surveillance.
Financial disclosure. None
6 OT4
THE EXPANDING SPECTRUM OF RETINAL VASOPRO-
LIFERATIVE TUMOURS
Jerry A. Shields MD, David Reichstein MD, Arman Mashayekhi MD, Carol
L. Shields MD (jerryshields@comcast.net)
Wills Eye Institute
Purpose. Retinal vasoproliferative tumor (RVPT) was originally
described as an idiopathic fundus lesion with distinct clinical features.
Subsequently, it found to be associated with a variety of ocular and
systemic conditions and was subdivided into primary and secondary types.
Methods. Review of lesions coded as retinal RVPT on the Oncology
Service of Wills Eye Institute and literature search for causes of
secondary retinal RVPTs
Results. The secondary form of RVPT has now been associated with a